Literature DB >> 25837033

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients.

Jennifer Hughes1, Petros Isaakidis2, Aristomo Andries2, Homa Mansoor2, Vivian Cox3, Graeme Meintjes4, Helen Cox5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25837033     DOI： 10.1183/09031936.00188114

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  12 in total

Review 1.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

2.  Target regimen profiles for treatment of tuberculosis: a WHO document.

Authors:  Christian Lienhardt; Payam Nahid; Michael L Rich; Cathy Bansbach; Emily A Kendall; Gavin Churchyard; Lice González-Angulo; Lia D'Ambrosio; Giovanni Battista Migliori; Mario Raviglione
Journal:  Eur Respir J       Date:  2017-01-25       Impact factor: 16.671

3.  Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.

Authors:  Mahmoud Tareq Abdelwahab; Sean Wasserman; James C M Brust; Keertan Dheda; Lubbe Wiesner; Neel R Gandhi; Robin M Warren; Frederick A Sirgel; Graeme Meintjes; Gary Maartens; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2021-09-20       Impact factor: 5.191

4.  Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.

Authors:  Sean Wasserman; James C M Brust; Mahmoud T Abdelwahab; Francesca Little; Paolo Denti; Lubbe Wiesner; Neel R Gandhi; Graeme Meintjes; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.758

Review 5.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

6.  Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.

Authors:  Sean Wasserman; Paolo Denti; James C M Brust; Mahmoud Abdelwahab; Siphokazi Hlungulu; Lubbe Wiesner; Jennifer Norman; Frederick A Sirgel; Robin M Warren; Aliasgar Esmail; Keertan Dheda; Neel R Gandhi; Graeme Meintjes; Gary Maartens
Journal:  Antimicrob Agents Chemother       Date:  2019-02-26       Impact factor: 5.191

7.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

8.  Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Authors:  Soazic Grard; Gaud Catho; Florent Valour; Anissa Bouaziz; Thomas Perpoint; Evelyne Braun; François Biron; Patrick Miailhes; Tristan Ferry; Christian Chidiac; Pierre-Jean Souquet; Sébastien Couraud; Gérard Lina; Sylvain Goutelle; Nicolas Veziris; Oana Dumitrescu; Florence Ader
Journal:  Open Forum Infect Dis       Date:  2015-12-22       Impact factor: 3.835

9.  Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Authors:  Emily A Kendall; Sourya Shrestha; Ted Cohen; Eric Nuermberger; Kelly E Dooley; Lice Gonzalez-Angulo; Gavin J Churchyard; Payam Nahid; Michael L Rich; Cathy Bansbach; Thomas Forissier; Christian Lienhardt; David W Dowdy
Journal:  PLoS Med       Date:  2017-01-03       Impact factor: 11.069

10.  Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.

Authors:  Salil Mehta; Mrinalini Das; Chinmay Laxmeshwar; Sylvie Jonckheere; Sein Sein Thi; Petros Isaakidis
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.